Semaglutide 2.4 mg: what it costs

2.4 mg is a price checkpoint as much as a clinical one. Here is what the board charges at this rung.

2.4 mg is step 5 of 5 on the semaglutide ladder, reached around weeks 17+. The maintenance dose for weight management, and the one behind the figure most people have read.

It is also the point where pricing starts to matter. On a programme that charges by dose, your bill climbs exactly as the treatment begins working. On a flat-rate programme, 2.4 mg costs what the starting dose cost — and over a full titration that difference is worth more than almost any advertised discount.

What the board does at this dose

Roughly half our listings hold one price from the starting dose to the maximum. The rest re-price as you climb, which means the figure that got you in the door is not the figure you pay by the time the medication is working. That is the gap this page exists to show.

What 2.4 mg is for

2.4 mg is the semaglutide dose behind the figure everyone quotes: roughly 14.9% average body-weight loss over 68 weeks in STEP-1. It is the maintenance target for weight management, and for many people the end of the ladder. Worth holding onto, though: that 14.9% is an average from a controlled trial with structured support, and about 60% of weight lost is regained within a year of stopping — so the more useful question at this rung is what the long-term plan looks like, not how fast you got here.

The evidence. In STEP-1, adults on 2.4 mg lost an average of about 14.9% of body weight over 68 weeks.

This is the target for many people, but not a requirement. Settling lower and tolerating it beats reaching 2.4 mg and stopping.

Where 2.4 mg sits on the ladder

Do you need to go higher than 2.4 mg?

2.4 mg is the top of the ladder, so the question here is the opposite one: whether you need to stay this high. Some people step back down to a lower maintenance dose once they have reached their goal. That is a conversation for your prescriber.

What happens when I reach 2.4 mg? For most people it becomes the ongoing maintenance dose rather than a finish line. Clinicians increasingly treat GLP-1 therapy the way they treat blood-pressure medication — something you stay on — which makes the monthly price a multi-year decision rather than a three-month one.

The board caveat: compounded is not FDA-approved, approved pills start at $149, and Medicare hits $50 on 1 July 2026. Any listing that ignores those three facts is selling, not reporting.